Tiny Packages for Delivering Gene-Targeting Drugs to Specific Cells
This patent describes a method to create tiny, targeted packages made of lipids and proteins that can deliver specific gene-modifying drugs, like antisense oligonucleotides, directly to certain cells in the body.
Original patent title: “Lipid nanoparticle compositions for antisense oligonucleotides delivery”
This patent describes a method to create tiny, targeted packages made of lipids and proteins that can deliver specific gene-modifying drugs, like antisense oligonucleotides, directly to certain cells in the body. Granted to The Ohio State University in 2019 with 35 claims and 3 forward citations, and it is expected to expire in 2033.
Coverage
What does this patent actually cover?
This patent describes a special type of tiny package called a lipid-coated albumin nanoparticle (LCAN) designed to deliver therapeutic agents. The LCAN is built around a core that is positively charged and contains an albumin-polycation conjugate, as specified in claimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 1. This core can encapsulate a therapeutic agent, such as an antisense oligonucleotide (ASO) that targets genes like Akt-1 or HIF-1, as detailed in claimsclaimsThe numbered statements at the end of a patent that legally define what the inventor owns.Read more → 2 and 3. The entire core is then wrapped in a positively-charged lipid layer, called a cationic liposome. Crucially, the nanoparticle also includes a 'targeting agent' (claim 1), which acts like a homing beacon to guide the package to specific cells or tissues, using molecules like RGD peptides or folate (claim 8). For example, this system could deliver an ASO to cancer cells, blocking a gene that helps them grow, while minimizing effects on healthy cells.
The gap
What does this patent NOT cover?
- Does not cover drug delivery systems that do not use a lipid-coated albumin nanoparticle (LCAN) structure as defined in claimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 1.
- Does not cover nanoparticles where the core is not net positively-charged or does not contain an albumin-polycation conjugate.
- Does not cover delivery systems that lack a specific targeting agent to direct the nanoparticle to certain cells.
- Does not cover lipid nanoparticles that are purely anionic or neutral in charge, as the claimsclaimsThe numbered statements at the end of a patent that legally define what the inventor owns.Read more → specify a 'cationic liposome' and a 'net positively-charged core'.
- Does not cover delivery of therapeutic agents that are not encapsulated within the core of the nanoparticle.
These exclusions are unique to PatentBrief — derived from the actual claim language, not patent-office boilerplate.
Key facts
What made this novel
The clever part is combining a stable, positively-charged protein-polycation core with a cationic lipid shell and a specific targeting agent. This creates a robust, targeted nanoparticle that can effectively encapsulate and deliver negatively-charged therapeutic agents like ASOs, ensuring they reach their intended cellular destination.
The Patent Drawing

Schematic visualization of the patent's claim structure. Hand-drawn diagrams in progress for each landmark patent.
Where you've seen this
Real-world examples
Targeted cancer therapies using nanoparticles
Gene therapy delivery systems
Antisense oligonucleotide (ASO) drug formulations
mRNA vaccine delivery (using lipid nanoparticles)
Drug delivery systems for inflammatory diseases
Why it matters
The bigger picture
This patent is important because it describes a way to make drug delivery more precise. By using 'targeting agents' and encapsulating drugs in stable nanoparticles, it aims to deliver medicines directly to diseased cells while avoiding healthy ones. This approach is crucial for therapies like antisense oligonucleotides (ASOs), which need to reach specific cells to work effectively and reduce unwanted side effects. It contributes to the broader field of nanomedicine, which seeks to revolutionize how drugs are administered.
Filed
May 23, 2013
Granted
June 4, 2019
Market context
Who's building on this
Companies in this space
Companies like Alnylam Pharmaceuticals and Ionis Pharmaceuticals are leaders in developing antisense oligonucleotide (ASO) therapies, often relying on advanced delivery systems. Many biotech startups and major pharmaceutical companies are actively researching and developing targeted nanoparticle delivery systems for various drugs, including gene therapies and oncology treatments. The Ohio State University, as the assigneeassigneeThe entity that owns the patent — usually the inventor's employer or a company.Read more →, also continues research in this area.
Market impact
This patent contributed to the growing field of targeted drug delivery, enabling more precise administration of therapeutic agents, particularly nucleic acid-based drugs like ASOs. By offering a method to create stable, targeted nanoparticles, it helped pave the way for therapies that can reduce systemic side effects and improve drug efficacy. This approach has become fundamental in the development of modern gene therapies and nanomedicines, influencing how new drugs are formulated and delivered to patients.
Claim 1 — Plain English
What this patent covers
This patent describes a special type of tiny package called a lipid-coated albumin nanoparticle (LCAN) designed to deliver therapeutic agents. The LCAN is built around a core that is positively charged and contains an albumin-polycation conjugate, as specified in claim 1. This core can encapsulate a therapeutic agent, such as an antisense oligonucleotide (ASO) that targets genes like Akt-1 or HIF-1, as detailed in claims 2 and 3. The entire core is then wrapped in a positively-charged lipid layer, called a cationic liposome. Crucially, the nanoparticle also includes a 'targeting agent' (claim 1), which acts like a homing beacon to guide the package to specific cells or tissues, using molecules like RGD peptides or folate (claim 8). For example, this system could deliver an ASO to cancer cells, blocking a gene that helps them grow, while minimizing effects on healthy cells.
The clever bit
The clever part is combining a stable, positively-charged protein-polycation core with a cationic lipid shell and a specific targeting agent. This creates a robust, targeted nanoparticle that can effectively encapsulate and deliver negatively-charged therapeutic agents like ASOs, ensuring they reach their intended cellular destination.
What it does not cover
- Does not cover drug delivery systems that do not use a lipid-coated albumin nanoparticle (LCAN) structure as defined in claim 1.
- Does not cover nanoparticles where the core is not net positively-charged or does not contain an albumin-polycation conjugate.
- Does not cover delivery systems that lack a specific targeting agent to direct the nanoparticle to certain cells.
- Does not cover lipid nanoparticles that are purely anionic or neutral in charge, as the claims specify a 'cationic liposome' and a 'net positively-charged core'.
- Does not cover delivery of therapeutic agents that are not encapsulated within the core of the nanoparticle.
Patent timeline
Application submitted to the patent office
Application published, typically 18 months after filing
Patent officially issued
Patent enters public domain
PatentBrief Score
Impact Score
Moderate
Citation count
12/40
Early citations
Claim breadth
20/20
Very broad protection
Recency
10/20
Granted 5–10 years ago
Assignee scale
0/20
Independent or smaller assigneeassigneeThe entity that owns the patent — usually the inventor's employer or a company.Read more →
PatentBrief Impact Score — based on citation count, claim breadth, recency, and assignee scale. Not a legal assessment.
Heuristic Value Estimate
What this patent might be worth
$126K – $403K
Midpoint $252K · 6.5 yr remaining · industry ×3.0
Heuristic only — blends forward/backward citation counts, claim scope, time remaining, litigation history, and CPC-derived industry baseline. Real valuations need a professional appraisal.
Claim text not yet imported for this patent
The original legal language
Original claims
35 claims as filed with the patent office.
Concepts involved
Citations
Patent lineage
Cite this patent
Lee, Y. B., Ahn, C. H., Kim, D. J., & Lee, R. J. (2019). Tiny Packages for Delivering Gene-Targeting Drugs to Specific Cells (U.S. Patent No. 10,307,490). U.S. Patent and Trademark Office. https://patentbrief.org/patent/us/10307490/lipid-nanoparticle-compositions-for-antisense-oligonucleotides-delivery
Auto-generated from the patent record. Double-check author order and the issue date against the official USPTO document before submitting.
Embed
Add this patent to your site
Drop this plain-English patent card into any blog post or article — free, no signup. It always links back to the full breakdown here.
<div data-patentlens-widget data-patent-number="US10307490"></div> <script src="https://patentbrief.org/embed.js" async></script>
Stay in the loop
Get a weekly digest of new patents.
One email per week. No spam. Unsubscribe anytime.
Keep exploring
Related patents you should know
US 4683195 · 1987
How to Make Billions of Copies of a DNA Segment
This patent describes the Polymerase Chain Reaction (PCR), a method to rapidly create many copies of a specific piece of DNA or RNA, enabling its detection and analysis.
Cetus Corp
US 8697359 · 2014
How to Edit Genes in Human Cells Using an Engineered CRISPR System
This patent describes an engineered CRISPR-Cas9 system for precisely cutting DNA in eukaryotic cells to change how genes work, opening the door for gene editing in complex organisms.
Massachusetts Institute of Technology
US 7657849 · 2010
How the iPhone's Slide-to-Unlock Gesture Works
Apple's 2010 patent describes unlocking a device by dragging a specific graphical image across the touchscreen along a predefined path, a gesture that became iconic with the original iPhone.
Apple Inc
US 4733665 · 1988
How Doctors Implant a Permanent Stent Using a Balloon
This patent describes the method for placing a permanent, expandable wire mesh tube inside a blood vessel or other body tube using a balloon-tipped catheter to widen it and keep it open.
Expandable Grafts Partnership
US 4965188 · 1990
How to Make Many Copies of a DNA Piece with Heat
This patent describes the Polymerase Chain Reaction (PCR) method, a technique to make millions of copies of a specific DNA segment using a heat-resistant enzyme and repeated temperature changes.
Cetus Corp
US 4235871 · 1980
How to Encapsulate Active Materials in Lipid Bubbles Efficiently
This patent describes a method for trapping biologically active substances inside tiny, multi-layered fat bubbles called liposomes, using a specific water-in-oil emulsion and gel-forming process to improve how much material gets captured.
Individual
Semantically similar
You might also find these interesting
US 11464870 · 2022 · Enhancedbio
Tiny Fat Bubbles That Deliver Drugs Directly to the Liver
US 20250235403 · Ohio State Innovation Foundation
Tiny Bubbles for Delivering Medicine
US 10155945 · 2018 · Nitto Denko Corp
How to Build Tiny Lipid Capsules to Deliver Genetic Medicines
US 20190046446 · Eriochem Usa
How Special Nanoparticles Deliver Cancer Drugs Directly to Tumors
More to explore
More in Biotech & Medicine
US 4683195 · 1987 · Cetus Corp
How to Make Billions of Copies of a DNA Segment
US 8697359 · 2014 · Massachusetts Institute of Technology
How to Edit Genes in Human Cells Using an Engineered CRISPR System
US 4733665 · 1988 · Expandable Grafts Partnership
How Doctors Implant a Permanent Stent Using a Balloon
US 4965188 · 1990 · Cetus Corp
How to Make Many Copies of a DNA Piece with Heat
New to patents?
Common Questions
Frequently Asked Questions
What does Tiny Packages for Delivering Gene-Targeting Drugs to Specific Cells cover?
This patent describes a method to create tiny, targeted packages made of lipids and proteins that can deliver specific gene-modifying drugs, like antisense oligonucleotides, directly to certain cells in the body.
Who owns patent US 10307490?
The Ohio State University owns this patent, granted in 2019.
When does this patent expire?
This patent is expected to expire on May 23, 2033, when the invention enters the public domain.
What is patent US 10307490 cited by?
This patent has been cited by 3 later patents that build on its ideas.
What problem does this patent solve?
This patent is important because it describes a way to make drug delivery more precise. By using 'targeting agents' and encapsulating drugs in stable nanoparticles, it aims to deliver medicines directly to diseased cells while avoiding healthy ones. This approach is crucial for therapies like antisense oligonucleotides (ASOs), which need to reach specific cells to work effectively and reduce unwanted side effects. It contributes to the broader field of nanomedicine, which seeks to revolutionize how drugs are administered.
What does this patent NOT cover?
Does not cover drug delivery systems that do not use a lipid-coated albumin nanoparticle (LCAN) structure as defined in claim 1.
Patent monitoring





